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ORIGINAL ARTICLE
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Abstract
Objective: Increasing asthma incidence may be due to an overall increase in asthma awareness
by physicians, potentially resulting in overdiagnosis. One of the unique features of asthma is
bronchial hyperresponsiveness, which can be assessed by methacholine bronchial challenge
(MBC). Overdiagnosis may result in over- or mistreatment. The aims of this study were to
describe the prevalence of the over-/misdiagnosis of asthma and the use of anti-asthmatic
drugs in patients with asthma-like symptoms who had not yet undergone a respiratory function
assessment to confirm the diagnosis of asthma. Methods: This was a retrospective study
analyzing all MBCs performed by our Outpatient Allergy Clinic in a two-year period to confirm/
exclude the diagnosis of asthma in patients referred by general practitioners and complaining
of asthma-like symptoms. Anti-asthmatic medications used by the patients until the MBC date
were recorded. Results: 43.8% of the reviewed MBCs were positive and 37.4% of the patients
with a positive MBC were previously taking anti-asthmatic drugs (568.8 ± 76.4mcg mean
beclomethasone equivalents), compared to 51.2% of those patients with a negative MBC
(464.8 ± 57.8mcg). No differences were found in the daily doses of inhaled corticosteroids or
other anti-asthmatic drugs, or in the duration of treatment before the assessment of bronchial
hyperresponsiveness. Conclusions: A sizeable percentage of subjects who reported physician-
diagnosed asthma had a negative MBC. Nevertheless, a greater proportion of negative
MBC patients were taking anti-asthmatic drugs compared to those with a confirmed diagnosis
of asthma, illustrating that the overdiagnosis of asthma may lead to over- and mistreatment
of respiratory symptoms.
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Introduction
In the past, the underdiagnosis of asthma by primary care
physicians was reported to be an important problem [1–4].
However, the intense focus on asthma as a prevalent and
treatable condition over the past decade may have resulted in
a heightened awareness among physicians and led to asthma
being more frequently diagnosed.
Unfortunately, an increase in the index of suspicion for
asthma in adults with respiratory complaints may also have
led to the mislabeling of non-asthmatic subjects as asthmatics.
There has been some attention in the popular media on the
overdiagnosis of asthma, and some studies have mentioned
this emerging clinical problem [5–8].
Inappropriate diagnosis of asthma is most likely to occur
when physicians rely on clinical evaluation alone rather than
objective testing. Asthma is defined as an inflammatory
disorder of the airways characterized by: (i) paroxysmal or
persistent symptoms (dyspnea, chest tightness, wheeze and
cough) with (ii) variable airflow limitation and (iii) airway
hyperresponsiveness to a variety of stimuli [9]. Presumably,
individuals not meeting these criteria may not suffer from
the disease.
One of the unique features of asthma, airway hyperrespon-
siveness, can be easily assessed with a methacholine bronchial
challenge (MBC), which consists of inhaling increasing doses
of methacholine and measuring lung function after each
inhalation. The concentration of medication required to
decrease FEV1 by 20% is noted (PC20FEV1) and considered
to be diagnostic. Unfortunately, MCB is time consuming and
may be uncomfortable for patients. As a result, this funda-
mental test is often underutilized in clinical practice.
The aims of this study were:
(1) to analyze the prevalence of positive MBCs in patients
complaining of asthma-like symptoms, with normal
spirometry, who were referred to an allergy clinic and
(2) to describe the use of anti-asthmatic drugs in patients
with respiratory symptoms before a formal diagnosis of
asthma by MBC, according to the drug prescription file
of the general practitioner (GP) of each enrolled patient.
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This was a retrospective study analyzing all MBCs performed
by our Allergy Outpatient Clinic from 1 January 2010 until 31
December 2012. All MBCs were performed to confirm the
diagnosis of asthma in patients referred by GPs and
complaining of asthma-like symptoms, but with normal
spirometry.
All MBCs were performed according to international
recommendations [10] and there was a minimum 7-day
washout period before the test.
Patients
According to our clinic database, approximately 100 patients/
year, referred by GP for suspected asthma, have been found to
have normal spirometry and were further tested using a MBC.
We reasoned that a two-year period appeared to be appropri-
ate to investigate how often the diagnosis of asthma could be
confirmed in these patients, taking into account that the
prevalence of misdiagnosis of had been previously reported to
be near 30% [8].
A total of 226 patients (130 females, 57.5%; mean age
37.4 ± 1.3 years, range: 15–70 years) who underwent the
MBC for asthma diagnosis have been included in the study.
All patients had been referred to the clinic for suspected
asthma by their GP. All patients who had asthma-like
symptoms and normal spirometry were included in the
study and the MBC result (positive or negative, according
to international guidelines) [9] was recorded.
Patients’ clinical records (including BMI) up to the date of
MBC were reviewed, and information regarding the patients
use of anti-asthmatic drugs was noted (type of treatment,
dosage, duration of treatment before MBC). The source of the
drug prescriptions data was the drug prescription file of the GP
of each enrolled patient. In Italy, all district inhabitants must
choose their GP and almost all GP drug prescriptions are saved
in electronic files. The doses of the different inhaled cortico-
steroids were converted to beclomethasone equivalents.
Evaluation of the direct cost of treatment
The pro-capita cost of treatment before the MBC assessment
was computed using the defined daily dose (DDD) index and
multiplied by the duration of treatment (number of days). The
DDD index is a statistical measure of drug consumption
defined by the World Health Organization to standardize the
comparison of drug usage between different drugs [11].
It should be emphasized that the DDD is a unit of
measurement and does not necessarily reflect the recom-
mended or prescribed daily dose. The DDD provides a fixed
unit of measurement, independent of price and dosage form
(e.g. tablet strength), enabling the researcher to assess trends
in drug consumption and to perform comparisons between
population groups.
Statistics
The sample size was determined by considering a 30%
estimated prevalence of misdiagnosis of asthma when the
diagnosis is not supported by respiratory function tests [8].
The clinic database identified that approximately 100
patients per year were referred by a GP for suspected asthma,
and on exhibiting normal spirometry, were evaluated using a
MBC. A two-year period was therefore considered an
appropriate duration for obtaining sufficient patient numbers.
A descriptive analysis of all known variables concerning
all included patients was performed. Continuous variables
were evaluated with the normality test of Kolmogorov–
Smirnov and compared with the ANOVA or Mann–Whitney
test, depending on the normality of the distribution.
Categorical variables were compared using Fisher’s exact
test. All data were analyzed using SPSS v. 20.0 software
(SPSS, Chicago, IL).
Results
Ninety-nine of the 226 (43.8%) patients had positive MBC
results, and 102 (45.1%) were using anti-asthmatic drugs
before undergoing the MBC.
The demographic and drug consumption data of the
patients compared by MBC results are reported in Table 1.
The proportion of patients already receiving anti-asthmatic
drugs was 45.1% (102/226 patients) and was significantly
lower in the subgroup of patients with a positive MBC
compared to those with a negative MBC (37.4% vs 51.2 %,
respectively, p¼ 0.038) (Figure 1). No significant differences
in body mass index, gender or age were found in the
comparison of patients with positive versus negative MBC or
treated asthma versus untreated patients.
The mean duration of treatment before MBC was
25.1 ± 4.4 months, and the mean daily dose of inhaled
corticosteroids expressed as beclomethasone equivalents was
503.3 ± 46.1 mcg. No significant difference was found for the
duration of treatment and beclomethasone equivalent dose
between patients with positive and negative MBCs.
Additionally, no difference was found between the use of
other anti-asthmatic drugs (i.e. long-acting beta2-agonists or
leukotriene-receptor antagonists) between those patients with
positive and negative MBCs.
The mean direct cost of treatment, expressed as DDD, was
722.1 ± 201.6 USD. Patients with a negative MBC had a
mean DDD of 965.3 ± 333.1 USD, which was higher than the
DDD of patients with a positive MBC (524.3 ± 169.7 USD,
p¼ 0.279), but the difference was not statistically significant
(Figure 2).
Discussion
The main result of this study is that a sizeable percentage of
subjects who report physician-diagnosed asthma and have
been previously treated for this disease have a negative MBC.
In patients with normal or near-normal spirometric values,
assessment of airway responsiveness is safe and significantly
better than other tests in discriminating patients with asthma
from patients with conditions commonly confused with
asthma. The test is sensitive so normal results provide the
strongest evidence against a diagnosis of asthma [12].
Yurdakul et al. [13] describe a much higher sensitivity for
MBC compared with FEV1 reversibility and PEFR variability
for asthma diagnosis among patients attending an outpatient
asthma clinic. Furthermore, Aaron et al. [8] suggest that





























asthma diagnosis could be confirmed in only 16% of patients
by means of post-bronchodilator spirometry at the time of
testing and in 72% of patients by means of bronchial
challenge testing with methacholine. Finally, Luks et al. [7]
suggest that only 10.8% of patients were diagnosed with
asthma using simple pre- and post-bronchodilator spirometry
at the time of testing, while MBC resulted in a confirmation
rate of 61.7% and an exclusion rate of 27.3% among
individuals whose lung function was reported to be in the
normal range at clinical presentation. Interestingly, a greater
proportion of patients with a negative MBC were taking anti-
asthmatic medications compared to those patients with a
confirmed diagnosis of asthma.
Taken together, these data reveal that there is consistently
over-/misdiagnosed asthma, which may lead to over- and
mistreatment of respiratory symptoms.
Many other conditions can cause symptoms similar to
those of asthma. The differential diagnosis of asthma includes
chronic obstructive pulmonary disease (COPD), chronic
bronchitis or emphysema, congestive heart failure, extra-
thoracic airway hyperresponsiveness syndromes (e.g. vocal
cord dysfunction, VCD), gastroesophageal reflux disease,
mechanical obstruction of the airways, tumor/neoplasm and
cough associated with upper airway disease (rhinitis and
rhinosinusitis). Infrequent causes of wheezing include pul-
monary embolism, pulmonary infiltrates with eosinophilia
and some medications (e.g. angiotensin-converting enzyme
inhibitors) [12]. Several of the above conditions may be
strongly suspected upon conducting a spirometric evaluation
(another underutilized tool in patients with respiratory
symptoms); for instance, COPD may be suspected by the
detection of a non-reversible bronchial obstruction, or
extrathoracic airway limitations may lead to suspicion of
VCD or other extrathoracic hyperresponsive syndromes.
The long duration of treatment with anti-asthmatic agents
(which was not significantly different in patients with
confirmed asthma compared to those with a negative MBC)
before performing MBC to confirm or exclude the diagnosis
of asthma confirms the underutilization of lung function tests
in respiratory disorders, despite the recommendations of
international guidelines that the diagnosis of asthma requires
the assessment of airway obstruction and its reversibility or
the assessment of airway hyperreactivity [9].
The direct cost of over- or mistreatment of respiratory
symptoms seems to be substantial. It is also interesting to note
that, in this study, the total cost of anti-asthmatic treatment
was higher in patients who were found to be non-asthmatic;
however, this was not significant.
Figure 1. Proportion of patients with positive
or negative MBC, and distribution of already
treated patients in the two group of patients
(‘‘Treated’’ vs ‘‘Naive’’).







p Value (positive vs
negative MBC patients)
Mean age 37.4 ± 1.3 years 37.0 ± 0.22 years 37.6 ± 1.6 years 0.622
Gender ratio (M/F) 0.74 0.68 0.79 0.578
Proportion of already treated patients 102/226 (45.1%) 37/99 (37.4%) 65/127 (51.2%) 0.038
Mean duration of treatment 25.1 ± 4.4 months 25.3 ± 7.6 months 24.9 ± 5.4 months 0.649
Mean daily bechlomethasone equivalents 503.3 ± 46.1 mcg 568.8 ± 76.4 mcg 464.8 ± 57.8 mcg 0.335
DDD days of treatment 772.1 ± 201.6 USD 524.3 ± 169.7 USD 965.3 ± 333.1 USD 0.279
Bold value represents statistical significance.
Figure 2. DDD for anti-asthmatic drugs multiplied for the duration of
treatment in patients with positive or negative MBC.





























The main limitation of this study is that it is retrospective
and not prospective, therefore providing limited information
on the final diagnosis of patients complaining asthma-like
symptoms without the evidence of airway hyperresponsive-
ness as these patients were lost at follow-up and referred to
other specialists (i.e. ENT, gastroenterologists, pneumolo-
gists, etc.) to make the final diagnosis and giving correct
treatment.
Conclusion
This study suggests that a clinical diagnosis not supported by
the lung function tests recommended by international guide-
lines may lead to the over-/misdiagnosis and over-/mistreat-
ment of asthma. Improving the systematic support and
education of GPs in diagnostic testing and decision-making
may diminish the prescription and overtreatment of inhaled
corticosteroids, thus reducing expensive and needless treat-
ment of non-asthmatic patients.
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